UHealth - University of Miami Health System

E-mail a Friend

Gabriel N. Contreras, M.D. MPH

General Information

Gabriel N. Contreras, M.D. MPH


  • Fax: 305-243-3506


  • Internal Medicine
  • Nephrology - Internal Medicine
  • Critical Care Medicine-Internal Medicine


English, Spanish

Clinical Areas

General nephrology, hypertension/resistant hypertension/ isolated systolic hypertension, glomerular disorders, renal vascular diseases, hemodialysis, peritoneal dialysis, renal transplantation, endstage renal disease/chronic renal insufficiency, kidney and liver diseases, critical care nephrology and renal replacement therapy in the ICU


  • American Board of Internal Med-Nephrology


  • Professor of Clinical Medicine

Research Interests

Hypertension, chronic kidney disease, lupus nephrtis



1999-2003 Master in Public Health
University of Miami, School of Public Health
Universidad Autonoma de Guadalajara
Universidad Nacional Autonoma de Mexico
Harlem Hospital Center, Columbia University
Jackson Memorial Hospital, University of Miami - Affiliated Medical Education Program


earned my medical degree in 1984 from the Autonomous University of Guadalajara in Mexico. I trained in Internal medicine, nephrology, hypertension, critical care, and earned a degree as Master in Public Health between 1989 and 2003. Subsequently, I joined the School of Medicine at the University of Miami. During my time as faculty in the Department of Medicine, I have been involved in the development and establishment of a successful clinical research program in the Division of Nephrology with the accrual of more than 21 research grants, 77 publications in peer review Journals, and 5 Chapters publications in textbooks. In the 19 years of my academic career, I have kept research funding from different sources such as the Kidney Foundation of South Florida, the Veterans Affairs Cooperative Study Program, the National Institute of Health (NIH) and the Pharmaceutical Industry. I have an ongoing commitment to improving kidney disease outcomes among racial and ethnic minorities and the public health throughout the clinical research program at the University of Miami, Miller School of Medicine. This is evidenced in part by maintaining funding for the University of Miami as a key site in the African American Study of Kidney Disease and Hypertension (AASK) trial-cohort, a multi-center, NIH-funded study of risk factors for the prevention and treatment of kidney disease progression among African Americans. I also participated as the site Principal Investigator of two important multicenter trials, the Homocysteine in End-stage Renal Disease and Chronic Renal Failure study and the Intensive versus Conventional Renal Support in Acute Renal Failure study funded by the Veterans Affairs Cooperative Study Program and the NIH, respectively. Currently, I am funded by the NIH as site principal investigator for the clinical trials: the Cardiovascular outcome in renal atherosclerotic lesions (CORAL) study and The Systolic Blood Pressure Intervention Trial (SPRINT) which results will provide guidelines to treat hypertension one of the most important health problem in the U.S. Additionally, I am funded as site principal investigator for the cohort The nephrotic syndrome study network (NEPTUNE) another study funded by the NIH. Along with the important work mentioned before, I have been also engaged in a number of internationally recognized clinical trials of novel treatments for lupus nephritis in racially and ethnically diverse populations. These trials are considered milestone studies that are improving the care of patients with lupus. The most important trial that I have so far participated is the Sequential Therapy for Proliferative Lupus Nephritis study, a milestone investigator-initiated trial partially sponsored by Roche pharmaceutical from 1996 to 2003. In that study, we demonstrated that for the treatment of severe lupus nephritis, sequential therapies with six of months of intravenous cyclophosphamide induction followed by either azathioprine or mycophenolate mofetil maintenance were more effective and safer reducing the risk for chronic kidney failure and death compared to prolong therapy with cyclophosphamide. That study culminated in a Worldwide read publication in the New England Journal of Medicine with a press release in the National Public Radio in 2004, many oral presentations in International meeting of Nephrology and Rheumatology, the launching of a transcontinental clinical trial concluded in 2010, and the most gratifying experience of improving the standard of care of lupus patients with the use of sequential therapies which currently are widely use as one of the first line regimens Worldwide. Currently, I am funded by the NIH as site principal investigator of two treatment trials for lupus nephritis: 1) Randomized, Double-Blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs. Cyclophosphamide Alone in the Treatment of Lupus Nephritis and, 2) Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients with Stable, Quiescent Systemic Lupus Erythematosus (SLE). I have published more than 21 papers and 1 book chapter in the area of lupus nephritis.

E-mail a Friend